Novartis Rises as $3.22 Billion Deal Targets Faster Drug Delivery
This article first appeared on GuruFocus. Novartis (NYSE:NVS), the global pharmaceutical and biotechnology powerhouse, slipped roughly 0.1% to…
Novartis signs deal worth up to $3.2 billion for Alteogen’s drug delivery technology
Sept 2 (Reuters) – South Korea’s Alteogen said on Wednesday it has signed a deal with Novartis worth…
Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products
Novartis obtains rights to develop and commercialize subcutaneous formulations for multiple products utilizing ALT-B4 Alteogen’s fourth licensing agreement…
Korea’s Alteogen inks $3.2 B deal with Novartis for development of Hybrozyme™-enabled subcutaneous products
Korea’s Alteogen inks $3.2 B deal with Novartis for development of Hybrozyme™-enabled subcutaneous products September 3, 2026 |…
Novartis signs deal worth up to $3.2 billion for Alteogen’s drug delivery technology
Sept 2 (Reuters) – South Korea’s Alteogen said on Wednesday it has signed a deal with Novartis worth…
Alteogen Signs $3.2 Billion Licensing Deal With Novartis
A view of Alteogen’s headquarters and research center. Photo courtesy of Alteogen Alteogen (196170.KQ) has signed a technology…
Alteogen Signs Up to $3.2 Billion Subcutaneous Injection Technology Export Deal with Novartis — BigGo Finance
Biopharmaceutical platform company Alteogen announced on September 2 that it has signed a technology export agreement with Swiss…
Alteogen has signed a subcutaneous injection (SC) formulation technology contract worth up to 4.4 tr..
Intravenous injection → Subcutaneous injection conversion formulation technologyNovartis Applied to multiple biopharmaceuticalsThe 4th technical contract this year…Royalty is…
Alteogen Licenses ALT-B4 Platform to Novartis in Deal Worth Up to $3.2 Billion
An exterior view of Alteogen’s headquarters and research center. Photo courtesy of Alteogen Alteogen (196170) has signed a…